145 related articles for article (PubMed ID: 35114805)
1. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites.
Zhan Z; Wang X; Yu J; Zheng J; Zeng Y; Sun M; Peng L; Guo Z; Chen B
Future Oncol; 2022 Mar; 18(10):1259-1271. PubMed ID: 35114805
[TBL] [Abstract][Full Text] [Related]
2. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis.
Biaoxue R; Xiguang C; Hua L; Wenlong G; Shuanying Y
BMC Cancer; 2016 Nov; 16(1):888. PubMed ID: 27842514
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal recombinant human endostatin combined with chemotherapy for refractory malignant ascites due to gastrointestinal cancer: a pilot study.
Xue SL; Deng X; Liu Y; Su HF; Hu ML; Xie CY
Hepatogastroenterology; 2013; 60(121):118-23. PubMed ID: 22784939
[TBL] [Abstract][Full Text] [Related]
4. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites.
Zhao WY; Chen DY; Chen JH; Ji ZN
Cell Biochem Biophys; 2014 Sep; 70(1):623-8. PubMed ID: 24920191
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
8. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
[TBL] [Abstract][Full Text] [Related]
9. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer.
Zhao J; Chen X; Zhang A; Xu F; Hu M; Xie C; Xue S
Med Oncol; 2014 Apr; 31(4):930. PubMed ID: 24659268
[TBL] [Abstract][Full Text] [Related]
11. Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion.
Chu H; Du F; Gong Z; Lian P; Wang Z; Li P; Hu B; Chi C; Chen J
Anticancer Res; 2017 Aug; 37(8):4587-4591. PubMed ID: 28739756
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
[TBL] [Abstract][Full Text] [Related]
13. [Clinical Observation of Recombinant Human Vascular Endostatin Durative Transfusion Combined with Window Period Arterial Infusion Chemotherapy in the Treatment of
Advanced Lung Squamous Carcinoma].
Lv Y; Jiang R; Ma C; Li J; Wang B; Sun L; Mu N
Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):500-4. PubMed ID: 26302347
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Zhang SL; Han CB; Sun L; Huang LT; Ma JT
Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
[TBL] [Abstract][Full Text] [Related]
15. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
16. Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer.
Gao SR; Li LM; Xia HP; Wang GM; Xu HY; Wang AR
Asian Pac J Cancer Prev; 2015; 16(9):4037-40. PubMed ID: 25987082
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of endostatin combined with continuous transcatheter arterial infusion and chemoembolization on gastric cancer with liver metastasis and analysis of prognosis.
Chen L; Shi H; Che Y; Sun W; Niu X; Lu W
J BUON; 2020; 25(3):1469-1475. PubMed ID: 32862592
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus.
Zhong Z; Gu X; Zhang Z; Wang D; Qing Y; Li M; Dai N
Br J Radiol; 2012 Nov; 85(1019):e1104-9. PubMed ID: 22898155
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.
Chen X; Liu Y; Yin Y; Jin S; Ping G; Røe OD; Yan K; Shu Y; Guo R
J Chemother; 2012 Aug; 24(4):231-6. PubMed ID: 23040690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
